The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma
Abstract
Purpose: We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ( 90 Y)–ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma in first remission. Patients and Methods: Patients with CD20 + stage III or IV follicular lymphoma, who achieved a complete response (CR)/unconfirmed CR (CRu) or partial response (PR) after first-line induction treatment, were randomly assigned to receive 90 Y-ibritumomab tiuxetan (rituximab 250 mg/m 2 on day −7 and day 0 followed on day 0 by 90 Y-ibritumomab tiuxetan 14.8 MBq/kg; maximum of 1,184 MBq) or no further treatment (control). The primary end point was progression-free survival (PFS), which was calculated from the time of random assignment. Results: A total of 414 patients (consolidation, n = 208; control, n = 206) were enrolled at 77 centers. 90 Y-ibritumomab tiuxetan consolidation significantly prolonged median PFS (after a median observation time of 3.5 years) in all patients (36.5 v 13.3 months in control arm; hazard ratio [HR] = 0.465; P < .0001) and regardless of whether patients achieved PR (29.3 v 6.2 months in control arm; HR = 0.304; P < .0001) or CR/CRu (53.9 v 29.5 months in control arm; HR = 0.613; P = .0154) after induction treatment. Median PFS with consolidation was prolonged in all Follicular Lymphoma International Prognostic Index risk subgroups. After 90 Y-ibritumomab tiuxetan consolidation, 77% of patients in PR after induction converted to CR/CRu, resulting in a final CR rate of 87%. The most common toxicity with 90 Y-ibritumomab tiuxetan was hematologic, and grade 3 or 4 infections occurred in 8% of patients. Conclusion: Consolidation of first remission with 90 Y-ibritumomab tiuxetan in advanced-stage follicular lymphoma is highly effective with no unexpected toxicities, prolonging PFS by 2 years and resulting in high PR-to-CR conversion rates regardless of type of first-line induction treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
Follicular lymphoma international prognostic index
Solal-Celigny, P. (2006) · Current Treatment Options in Oncology · doi:10.1007/s11864-006-0036-3 · Cited by 1,339
Hiddemann, W. (2005) · Blood · doi:10.1182/blood-2005-01-0016 · Cited by 1,320
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Marcus, R. (2005) · Blood · doi:10.1182/blood-2004-08-3175 · Cited by 967
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Self-citationWitzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.017 · Cited by 651
Follicular Lymphoma International Prognostic Index
Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2003-12-4434 · Cited by 626
Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3793 · Cited by 539
Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., & Grillo-López, A. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.020 · Cited by 366
Johnson, P. W., Rohatiner, A. Z., Whelan, J. S., Price, C. G., Love, S., Lim, J., Matthews, J., Norton, A. J., Amess, J. A., & Lister, T. A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.140 · Cited by 337
Self-citationWitzig, T. E., White, C. A., Gordon, L. I., Wiseman, G. A., Emmanouilides, C., Murray, J. L., Lister, J., & Multani, P. S. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.043 · Cited by 289
Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., & Fisher, R. I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8198 · Cited by 280
Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311253292203 · Cited by 268
Wiseman, G. A., Gordon, L. I., Multani, P. S., Witzig, T. E., Spies, S., Bartlett, N. L., Schilder, R. J., Murray, J. L., Saleh, M., Allen, R. S., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4336 · Cited by 264
Leonard, J. P., Coleman, M., Kostakoglu, L., Chadburn, A., Cesarman, E., Furman, R. R., Schuster, M. W., Niesvizky, R., Muss, D., Fiore, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.803 · Cited by 158
Zinzani, P. L., Pulsoni, A., Perrotti, A. P., Soverini, S., Zaja, F. F., Renzo, A. D., Storti, S., Lauta, V. M., Guardigni, L., Gentilini, P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.170 · Cited by 143
Self-citationThiéblemont, C., & Coiffier, B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5957 · Cited by 142
Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients
Liang, R., Anderson, Jr., Armitage, J. O., Berger, F., Cavalli, F., Chan, W., Close, J., Coiffier, B., Connors, J. M., Diebold, J., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008205619617 · Cited by 114
Emmanouilides, C. E., Witzig, T. E., Gordon, L. I., Vo, K., Wiseman, G. A., Flinn, I. W., Darif, M., Schilder, R. J., & Molina, A. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500376076 · Cited by 85
The clinical course of follicular lymphoma
Rohatiner, A. Z. S., & Lister, T. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.06.002 · Cited by 55
Self-citationSafety and Efficacy of Yttrium-90 Ibritumomab Tiuxetan in Older Patients With Non-Hodgkin's Lymphoma
Emmanouilides, C. E., Witzig, T. E., Wiseman, G. A., Gordon, L. I., Wang, H., Schilder, R. J., Saville, M. W., Flinn, I. W., & Molina, A. (2007) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2007.359 · Cited by 45
Harris, N. L. (1997) · Annals of Oncology · doi:10.1093/annonc/8.suppl_2.s11 · Cited by 41
Jankowitz, R. C., Foon, K. A., DeMonaco, N. A., Osborn, J. L., Wu, M.-C., Evans, T. L., Swerdlow, S. H., JOYCE, J. M., Land, S. R., & Jacobs, S. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8005 · Cited by 8
Cited by
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Dreyling, M., Campo, E., Hermine, O., Jerkeman, M., Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., & Ladetto, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx223 · Cited by 741
Shankland, K. R., Armitage, J. O., & Hancock, B. W. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60605-9 · Cited by 641
Radioimmunotherapy of human tumours
Larson, S. M., Carrasquillo, J. A., Cheung, N.-K. V., & Press, O. W. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3925 · Cited by 537
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Metadata
- Authors
- Morschhauser, F., Radford, J., Van Hoof, A., Vitolo, U., Soubeyran, P., Tilly, H., Huijgens, P. C., Kolstad, A., d’Amore, F., Diaz, M. G., Petrini, M., Sebban, C., Zinzani, P. L., van Oers, M. H. J., van Putten, W., Bischof-Delaloye, A., Rohatiner, A., Salles, G., Kuhlmann, J., & Hagenbeek, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-11-10
- Volume
- 26
- Issue
- 32
- Pages
- 5156-5164
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2132443196
- Cited by
- 460
- References
- 25
- FWCI
- 32.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.